Halozyme Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 130.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.86B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...